Dimitrios H Roukos

List of Publications by Citations

120 papers	6,353 citations	57 h-index	75 g-index
236 ext. papers	6,975 ext. citations	4.6 avg, IF	6.58 L-index

#	Paper	IF	Citations
120	Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *International Journal of Cancer*, **2006**, 118, 2559-66	7.5	258
119	Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). *Journal of the National Cancer Institute*, **2006**, 98, 345-54	9.7	247
118	The role of heat shock proteins in cancer. *Cancer Letters*, **2015**, 360, 114-8	9.9	199
117	Perspectives in the treatment of gastric cancer. *Nature Clinical Practice Oncology*, **2005**, 2, 98-107		146
116	The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. *Cancer Treatment Reviews*, **2004**, 30, 205-11	14.4	129
115	Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. *Surgery*, **1998**, 123, 573-8	3.6	126
114	Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. *Nature Clinical Practice Oncology*, **2007**, 4, 578-90		107
113	Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. *Annals of Surgical Oncology*, **1999**, 6, 46-56	3.1	106
112	Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. *Cancer Biology and Therapy*, **2007**, 6, 308-12	4.6	104
111	The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. *Annals of Surgical Oncology*, **2008**, 15, 21-33	3.1	101
110	Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. *Annals of Surgical Oncology*, **2009**, 16, 772-3	3.1	97
109	Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. *International Journal of Cancer*, **2012**, 131, 2910-9	7.5	93
108	Application of microRNAs in diabetes mellitus. *Journal of Endocrinology*, **2014**, 222, R1-R10	4.7	91
107	Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the "Gordian Knot"?. *Annals of Surgical Oncology*, **2009**, 16, 774-5; author reply 776-7	3.1	85
106	Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. *Expert Review of Molecular Diagnostics*, **2010**, 10, 33-48	3.8	82
105	Individual genomes and personalized medicine: life diversity and complexity. *Personalized Medicine*, **2010**, 7, 347-350	2.2	81
104	Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. *Annals of Surgical Oncology*, **2009**, 16, 1771-82	3.1	80

103	More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. *Annals of Surgical Oncology*, **2008**, 15, 956-60	3.1	80
102	Early-stage gastric cancer: a highly treatable disease. *Annals of Surgical Oncology*, **2004**, 11, 127-9	3.1	77
101	Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. *Annals of Surgical Oncology*, **2000**, 7, 719-26	3.1	77
100	Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. *Expert Review of Molecular Diagnostics*, **2008**, 8, 587-97	3.8	75
99	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. *Expert Review of Molecular Diagnostics*, **2008**, 8, 29-39	3.8	75
98	Genomics and challenges toward personalized breast cancer local control. *Journal of Clinical Oncology*, **2008**, 26, 4360-1; author reply 4361-2	2.2	75
97	Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. *Journal of Clinical Oncology*, **2009**, 27, 1337-8; author reply 1338-9	2.2	74
96	Factors increasing local recurrence in breast-conserving surgery. *Expert Review of Anticancer Therapy*, **2005**, 5, 737-45	3.5	72
95	Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. *Expert Review of Anticancer Therapy*, **2006**, 6, 931-9	3.5	69
94	Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. *Annals of Surgery*, **2009**, 249, 1067-8	7.8	67
93	Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. *Annals of Surgery*, **2008**, 247, 714-5; author reply 715-6	7.8	67
92	A critical evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach. An analysis of early results and long-term survival. *Journal of Cancer Research and Clinical Oncology*, **1990**, 116, 307-13	4.9	66
91	Linking contralateral breast cancer with genetics. *Radiotherapy and Oncology*, **2008**, 86, 139-41	5.3	65
90	Robotic surgery for rectal cancer: may it improve also survival?. *Surgical Endoscopy and Other Interventional Techniques*, **2008**, 22, 1405-6	5.2	63
89	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. *Pharmacogenomics Journal*, **2011**, 11, 81-92	3.5	58
88	Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. *Annals of Surgery*, **2009**, 250, 349-50; author reply 350	7.8	58
87	Breast-cancer stromal cells with TP53 mutations. *New England Journal of Medicine*, **2008**, 358, 1636; author reply 1636	59.2	52
86	Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true?. *Annals of Surgery*, **2009**, 249, 695-6; author reply 697	7.8	50

85	Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. *Annals of Surgery*, **2009**, 250, 650-1; author reply 651	7.8	49
84	Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?. *Surgical Endoscopy and Other Interventional Techniques*, **2008**, 22, 1402-4	5.2	43
83	Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). *Scandinavian Journal of Gastroenterology*, **2007**, 42, 618-27	2.4	41
82	Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. *Journal of Clinical Oncology*, **2010**, 28, e279-80; author reply e282-3	2.2	32
81	Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. *Modern Pathology*, **2012**, 25, 1055-68	9.8	31
80	HER2 and response to paclitaxel in node-positive breast cancer. *New England Journal of Medicine*, **2008**, 358, 197; author reply 198	59.2	30
79	Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. *New England Journal of Medicine*, **2007**, 357, 1555-6; author reply 1556	59.2	29
78	Continuous intraoperative neuromonitoring in thyroid surgery: Safety analysis of 400 consecutive electrode probe placements with standardized procedures. *Head and Neck*, **2016**, 38 Suppl 1, E1568-74	4.2	26
77	Comprehensive intra-individual genomic and transcriptional heterogeneity: Evidence-based Colorectal Cancer Precision Medicine. *Cancer Treatment Reviews*, **2019**, 80, 101894	14.4	22
76	Impact of spleen preservation in patients with gastric cancer. *Anticancer Research*, **2005**, 25, 3023-30	2.3	22
75	Chromatin: a key player in complex gene regulation and future cancer therapeutics. *Epigenomics*, **2011**, 3, 395-9	4.4	20
74	Spatiotemporal diversification of intrapatient genomic clones and early drug development concepts realize the roadmap of precision cancer medicine. *Drug Discovery Today*, **2017**, 22, 1148-1164	8.8	17
73	Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. *OncoTargets and Therapy*, **2014**, 7, 491-500	4.4	17
72	Laparoscopic gastrectomy for gastric cancer: current evidences. *International Journal of Surgery*, **2014**, 12, 1369-73	7.5	16
71	Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks. *Expert Review of Anticancer Therapy*, **2010**, 10, 1187-95	3.5	16
70	Dynamic genome and transcriptional network-based biomarkers and drugs: precision in breast cancer therapy. *Medicinal Research Reviews*, **2019**, 39, 1205-1227	14.4	15
69	Drug resistance: origins, evolution and characterization of genomic clones and the tumor ecosystem to optimize precise individualized therapy. *Drug Discovery Today*, **2019**, 24, 1281-1294	8.8	12
68	Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies. *Drug Discovery Today*, **2016**, 21, 663-73	8.8	12

67	Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery. *Current Pharmaceutical Design*, **2014**, 20, 11-22	3.3	12
66	BMI and lymph node ratio may predict clinical outcomes of gastric cancer. *Future Oncology*, **2014**, 10, 249-55	3.6	10
65	Research and clinical applications of cancer genome sequencing. *Current Opinion in Obstetrics and Gynecology*, **2013**, 25, 3-10	2.4	10
64	Bulk and Single-Cell Next-Generation Sequencing: Individualizing Treatment for Colorectal Cancer. *Cancers*, **2019**, 11,	6.6	10
63	Laparoscopic and robotic rectal cancer resection: expectations for improving oncological outcomes. *Annals of Surgery*, **2010**, 251, 185-6; author reply 186	7.8	9
62	From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	8
61	Contralateral prophylactic mastectomy: mind the genetics. *Journal of Clinical Oncology*, **2008**, 26, 1909-10; author reply 1910	2.2	8
60	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. *Drug Discovery Today*, **2018**, 23, 1848-1872	8.8	7
59	Intraoperative neuromonitoring of the external branch of the superior laryngeal nerve during thyroidectomy: the need for evidence-based data and perioperative technical/technological standardization. *Scientific World Journal, The*, **2014**, 2014, 692365	2.2	7
58	EGFR as a Prognostic Marker for Gastric Cancer. *World Journal of Surgery*, **2008**, 32, 1225-6; author reply 1227-9	3.3	7
57	Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. *Annals of Surgical Oncology*, **2008**, 15, 2981-2; author reply 2983-5	3.1	7
56	Genome network medicine: innovation to overcome huge challenges in cancer therapy. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, **2014**, 6, 201-8	6.6	6
55	Translating cancer genomes sequencing revolution into surgical oncology practice. *Journal of Surgical Research*, **2012**, 173, 365-9	2.5	6
54	Identification of novel genes by whole-exome sequencing can improve gastric cancer precision oncology. *Future Oncology*, **2017**, 13, 883-892	3.6	5
53	Totally laparoscopic gastrectomy: a reality for USA and Europe?. *Annals of Surgical Oncology*, **2009**, 16, 2665-6; author reply 2667	3.1	5
52	Fruits and vegetables: do they protect from gastric cancer?. *Gastroenterology*, **2003**, 124, 2006-7; author reply 2007	13.3	5
51	Dynamic sequencing of circulating tumor DNA: novel noninvasive cancer biomarker. *Biomarkers in Medicine*, **2014**, 8, 629-32	2.3	4
50	Surgery in the era of gene expression profiling-based prediction and individualized, neoadjuvant breast cancer therapy: the beginning of the end?. *Annals of Surgical Oncology*, **2006**, 13, 433-5	3.1	4

49	Breast and gastric cancer: comparing what we learn. *Annals of Surgical Oncology*, **2003**, 10, 92-4	3.1	4
48	Relevant prognostic factors in gastric cancer. *Annals of Surgery*, **2000**, 232, 719-20	7.8	4
47	Integrative deep-sequencing analysis of cancer samples: discoveries and clinical challenges. *Pharmacogenomics Journal*, **2013**, 13, 205-8	3.5	3
46	Omitting axilla lymphadenectomy even by positive sentinel lymph node: a change in breast cancer treatment practice. *Womens Health*, **2011**, 7, 417-8	3	3
45	HER-2-negative breast cancer limitations and next-generation sequencing technology promises. *Annals of Surgical Oncology*, **2010**, 17, 1720	3.1	3
44	Totally intracorporeal laparoscopic gastrectomy for gastric cancer. *Surgical Endoscopy and Other Interventional Techniques*, **2010**, 24, 3247-8; author reply 3249-50	5.2	3
43	Can VEGF-D and VEGFR-3 be used as biomarkers for therapeutic decisions in patients with gastric cancer?. *Nature Clinical Practice Oncology*, **2006**, 3, 418-9		3
42	Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?. *Nature Clinical Practice Oncology*, **2006**, 3, 656-7		3
41	Effectiveness of extended lymphadenectomy in early gastric cancer. *Surgery*, **1996**, 119, 238-9	3.6	3
40	Limitations of isolated tumor cells in gastric cancer: heterogeneity requests systems biology approaches towards personalized medicine. *Annals of Surgical Oncology*, **2010**, 17, 343-4; author reply 345	3.1	2
39	HER2 and trastuzumab: impact of a new standard agent on local control and surgery for breast cancer. *Annals of Surgical Oncology*, **2008**, 15, 3614-5; author reply 3616	3.1	2
38	Effectiveness of extended lymphadenectomy in noncurative gastrectomy. *American Journal of Surgery*, **1996**, 172, 303	2.7	2
37	Primary liver cancer genome sequencing: translational implications and challenges. *Expert Review of Gastroenterology and Hepatology*, **2017**, 11, 875-883	4.2	2
36	Intratumor heterogeneity: predicting and preventing therapeutic resistance. *Biomarkers in Medicine* , **2016**, 10, 681-4	2.3	1
35	Next-Generation Sequencing & Molecular Diagnostics **2013**,		1
34	Standards, advances and challenges in laparoscopic total mesorectal excision. *Surgical Endoscopy and Other Interventional Techniques*, **2011**, 25, 333-5	5.2	1
33	Challenges in personalizing decisions on whole, partial or no breast irradiation and extent of surgery for early breast cancer. *Annals of Surgical Oncology*, **2009**, 16, 2656-7; author reply 2658	3.1	1
32	Comparative-effectiveness research to standardize retrieved nodes for quality control in colorectal cancer. *Annals of Surgery*, **2010**, 252, 202-3; author reply 203	7.8	1

31	Quality control in colorectal cancer care: how many lymph nodes should be harvested?. *World Journal of Surgery*, **2010**, 34, 864-5; author reply 866-7	3.3	1
30	Does lymphadenectomy improve survival of patients with solid tumors?. *Annals of Surgical Oncology*, **2008**, 15, 385; author reply 388-9	3.1	1
29	Increased risk of local recurrence after breast-conserving therapy in young patients. *Radiotherapy and Oncology*, **2008**, 86, 286-7; author reply 287-8	5.3	1
28	Does neoadjuvant versus adjuvant systemic treatment improve outcomes in breast cancer?. *Nature Clinical Practice Oncology*, **2005**, 2, 342-3		1
27	Is an aromatase inhibitor more effective than tamoxifen in neoadjuvant endocrine therapy for breast cancer?. *Nature Clinical Practice Oncology*, **2006**, 3, 82-3		1
26	It Is Still Not the Time to Change Surgical Strategy for Gastric Cancer. *Annals of Surgical Oncology*, **2005**, 12, 194-196	3.1	1
25	Adjuvant chemotherapy in gastric cancer. *Journal of Clinical Oncology*, **2000**, 18, 3061-2	2.2	1
24	Targeting the individual cancer patient **2011**, 8-28		1
23	Early solid tumor diagnosis through next-generation sequencing of cell-free DNA. *Biomarkers in Medicine*, **2018**, 12, 1197-1201	2.3	1
22	Next-Generation Sequencing in Cancer Epigenomics and Potential Clinical Applications **2013**, 31-53		1
21	Proof-of-Concept Pilot Study on Comprehensive Spatiotemporal Intra-Patient Heterogeneity for Colorectal Cancer With Liver Metastasis.. *Frontiers in Oncology*, **2022**, 12, 855463	5.3	1
20	Precision oncology in patients with nonmetastatic disease: emerging reality or illusion. *Future Oncology*, **2019**, 15, 1805-1810	3.6	
19	The Evolution of High-Throughput Sequencing Technologies: From Sanger to Single-Molecule Sequencing **2013**, 1-30		
18	Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients. *Tumori*, **2015**, 101, 511-6	1.7	
17	Integrating NGS and third-generation sequencing technologies into clinical genomic medicine **2013**, 6-18		
16	Translating complex genomic discoveries into molecular diagnostic tests **2013**, 2-5		
15	Esophagus and Gastric Cancer: How Surgeons' Experience and Personal Genomics May Improve Locoregional Control and Survival. *World Journal of Surgery*, **2009**, 33, 161-2	3.3	
14	Circulating cancer cells: could they be used in the clinic as recurrence markers for gastric and colorectal cancer?. *Annals of Surgical Oncology*, **2009**, 16, 778-9; author reply 780-2	3.1	

13	Magnetic resonance imaging and potential impact on extent of surgery in breast cancer. *Annals of Surgical Oncology*, **2009**, 16, 2953-4; author reply 2955	3.1
12	Standardizing lymphadenectomy for rectal cancer. *Annals of Surgery*, **2010**, 252, 569; author reply 569-70	7.8
11	Caution in adding bevacizumab in the adjuvant treatment of breast cancer. *Annals of Surgical Oncology*, **2010**, 17, 653-4; author reply 655-6	3.1
10	Ten years after human genome sequencing: is personalized breast screening and prevention reality?. *World Journal of Surgery*, **2010**, 34, 2786-7; author reply 2788-9	3.3
9	Thresholds and combined quality control in the multimodal treatment of colorectal cancer. *Surgical Endoscopy and Other Interventional Techniques*, **2010**, 24, 1789-90	5.2
8	New technology-based innovation changes surgical practice and research direction in solid cancers. *Surgical Endoscopy and Other Interventional Techniques*, **2010**, 24, 2916-7	5.2
7	Hope from Japan for esophagogastric cancers: esophagectomy and endoscopic submucosal dissection for gastric tube cancer. *Surgical Endoscopy and Other Interventional Techniques*, **2010**, 24, 2924-5	5.2
6	Outcomes of breast cancer patients with and without BRCA1/2 mutations. *International Journal of Cancer*, **2008**, 122, 1918-9	7.5
5	A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. *Annals of Surgery*, **1996**, 224, 108-9	7.8
4	Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future **2015**, 317-330	
3	Personalized genomic medicine: is a cancer care revolution achievable? **2011**, 2-6	
2	Precision in personalized prediction-based medicine. *Personalized Medicine*, **2018**, 15, 467-470	2.2
1	Breakthrough cancer genome analysis in time and space: novel oncotargets and early drug development. *Pharmacogenomics*, **2018**, 19, 1303-1310	2.6